[1]
|
Ye, L., Ren, Y., Zhou, X., et al. (2019) Decitabine Improves Overall Survival in Myelodysplastic Syndromes-RAEB Patients Aged ≥ 60 Years and Has Lower Toxicities: Comparison with Low-Dose Chemotherapy. Blood Cells, Molecules, and Diseases, 77, 88-94. https://doi.org/10.1016/j.bcmd.2019.03.010
|
[2]
|
Boultwood, J. and Wainscoat, J.S. (2007) Gene Silencing by DNA Methylation in Haematological Malignancies. British Journal of Haematology, 138, 3-11. https://doi.org/10.1111/j.1365-2141.2007.06604.x
|
[3]
|
Huang, Y.W., Kuo, C.T., Stoner, K., et al. (2011) An Overview of Epigenetics and Chemoprevention. FEBS Letters, 585, 2129-2136. https://doi.org/10.1016/j.febslet.2010.11.002
|
[4]
|
Ye, X.N., Zhou, X.P., Wei, J.Y., et al. (2016) Epigenetic Priming with Decitabine Followed by Low-Dose Idarubicin/Cytarabine Has an Increasedanti-Leukemic Effect Compared to Traditional Chemotherapy in High-Riskmyeloid Neoplasms. Leukemia & Lymphoma, 57, 1311-1318. https://doi.org/10.3109/10428194.2015.1091931
|
[5]
|
Zeidan, A.M., Stahl, M., Sekeres, M.A., et al. (2017) A Call for Action: Increasing Enrollment of Untreated Patients with Higher-Riskmyelodysplastic Syndromes in First-Line Clinical Trials. Cancer, 123, 3662-3672. https://doi.org/10.1002/cncr.30903
|
[6]
|
Römermann, D., Hasemeier, B., Metzig, K., et al. (2008) Global Increase in DNA Methylation in Patients with Myelodysplastic Syndrome. Leukemia, 22, 1954-1956. https://doi.org/10.1038/leu.2008.76
|
[7]
|
Li, X., Song, Q., Chen, Y., et al. (2014) Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis. PLOS ONE, 9, e95473. https://doi.org/10.1371/journal.pone.0095473
|
[8]
|
Kantarjian, H., Issa, J.P., Rosenfeld, C.S., et al. (2006) Decitabine Improves Patient Outcomes in Myelodysplastic Syndromes: Results of Aphase III Randomized Study. Cancer, 106, 1794-1803. https://doi.org/10.1002/cncr.21792
|
[9]
|
Liibbert, M., Suciu, S., Baila, L., et al. (2011) Low-Dose Decitabine versus Best Supportive Care in Elderly Patients with Intermediate or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Journal of Clinical Oncology, 29, 1987-1996. https://doi.org/10.1200/JCO.2010.30.9245
|
[10]
|
Kantarjian, H., O’Brien, S., Huang, X., et al. (2007) Survival Advantage with Decitabine versus Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome: Comparison with Historical Experience. Cancer, 109, 1133-1137. https://doi.org/10.1002/cncr.22508
|
[11]
|
Wu, L., Li, X., Chang, C., et al. (2016) Efficacy and Toxicity of Decitabine versus CHG Regimen (Low-Dose Cytarabine, Homoharringtonine and Granulocyte Colonystimulating Factor) in Patients with Higher Risk Myelodysplastic Syndrome: A Retrospective Study. Leukemia & Lymphoma, 57, 1367-1374. https://doi.org/10.3109/10428194.2015.1096351
|
[12]
|
徐泽锋, 秦铁军, 张宏丽, 等. 地西他滨单药与CAG/HAG方案治疗难治性贫血伴有原始细胞增多的疗效和安全性比较[J]. 中华血液学杂志, 2017, 38(7): 572-577.
|
[13]
|
王萌, 韩好好, 郭荣, 等. 低剂量地西他滨序贯CAG方案治疗MDS-难治性贫血伴有原始细胞过多的临床疗效[J]. 中国实验血液学杂志, 2017, 25(5): 1482-1486.
|
[14]
|
Kantarjian, H., Oki, Y., Garcia-Manero, G., et al. (2007) Results of a Randomized Study of 3 Schedules of Low-Dose Decitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Blood, 109, 52-57. https://doi.org/10.1182/blood-2006-05-021162
|
[15]
|
Wu, D., Du, X., Jin, J., et al. (2015) Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study. Advanced Therapeutics, 32, 1140-1159. https://doi.org/10.1007/s12325-015-0263-8
|
[16]
|
吴东, 李晓, 常春康, 等. 地西他滨治疗骨髓增生异常综合征患者后粒细胞受抑的临床分析[J]. 中华血液学杂志, 2014, 35(2): 173-175.
|
[17]
|
吴东, 张耀, 赵佑山, 等. 地西他滨对MDS-L细胞增殖的抑制作用及其相关作用机制研究[J]. 中国实验血液学杂志, 2017, 25(5): 1471-1476.
|
[18]
|
雒雪萍, 徐泽锋, 秦铁军, 等. 地西他滨治疗难治性贫血伴有原始细胞过多的疗效和不良反应与治疗疗程数的关系[J]. 中华血液学杂志, 2016, 37(10): 870-875.
|
[19]
|
张前鹏, 韩永胜, 皖湘, 等. 地西他滨与传统化疗治疗中、高危骨髓增生异常综合征的临床比较[J]. 中国实验血液学杂志, 2018, 26(1): 197-201.
|
[20]
|
Cabrero, M., Jabbour, E., Ravandi, F., et al. (2015) Discontinuation of Hypomethylating Agent Therapy in Patients with Myelodysplastic Syndromes or Acute Myelogenous Leukemia in Complete Remission or Partial Response: Retrospective Analysis of Survival after Long-Term Follow-Up. Leukemia Research, 39, 520-524. https://doi.org/10.1016/j.leukres.2015.03.006
|
[21]
|
Lubbert, M., Bertz, H., Ruter, B., et al. (2009) Non-Intensive Treatment with Low-Dose 5-Aza-2’-Deoxycytidine (DAC) Prior to Allogeneic Blood SCT of Older MDS/AML Patients. Bone Marrow Transplantation, 44, 585-588. https://doi.org/10.1038/bmt.2009.64
|
[22]
|
De Padua Silva, L., De Lima, M., Kantarjian, H., et al. (2009) Feasibility of Allo-SCT after Hypomethylating Therapy with Decitabine for Myelodysplastic Syndrome. Bone Marrow Transplantation, 43, 839-843. https://doi.org/10.1038/bmt.2008.400
|
[23]
|
郑慧菲, 王婧, 周进, 等. 地西他滨桥接异基因造血干细胞移植治疗骨髓增生异常综合征的疗效分析[J]. 中华血液学杂志, 2015, 36(2): 121-123.
|
[24]
|
Schroeder, T., Rautenberg, C., Kruger, W., et al. (2018) Treatment of Relapsed AML and MDS after Allogeneic Stem Cell Transplantation with Decitabine and DLI—A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group. Annals of Hematology, 97, 335-342. https://doi.org/10.1007/s00277-017-3185-5
|
[25]
|
Ueda, M., El-Jurdi, N., Cooper, B., et al. (2019) Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse. Biology of Blood and Marrow Transplantation, 25, 1122-1127. https://doi.org/10.1016/j.bbmt.2018.12.764
|
[26]
|
Craddock, C., Slade, D., De Santo, C., et al. (2019) Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse after Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. Journal of Clinical Oncology, 37, 580-588. https://doi.org/10.1200/JCO.18.00889
|
[27]
|
Della Porta, M.G., Galli, A., Bacigalupo, A., et al. (2016) Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients with Myelodysplastic Syndromes Treated with Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 34, 3627-3637. https://doi.org/10.1200/JCO.2016.67.3616
|
[28]
|
Welch, J.S., Petti, A.A., Miller, C.A., et al. (2016) TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. The New England Journal of Medicine, 375, 2023-2036. https://doi.org/10.1056/NEJMoa1605949
|